Bicara Therapeutics Common Stock Performance
| BCAX Stock | 16.19 0.08 0.50% |
The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicara Therapeutics is expected to be smaller as well. At this point, Bicara Therapeutics has a negative expected return of -0.11%. Please make sure to confirm Bicara Therapeutics' coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if Bicara Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bicara Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.5 | Five Day Return (4.60) | Year To Date Return (1.16) | Ten Year Return (30.84) | All Time Return (30.84) |
1 | Disposition of 11445 shares by Mazumdar Claire of Bicara Therapeutics at 18.9205 subject to Rule 16b-3 | 10/13/2025 |
2 | Discretionary transaction by Ra Capital Management, L.p. of 1172334 shares of Bicara Therapeutics subject to Rule 16b-3 | 11/04/2025 |
3 | Wedbush Equities Analysts Lower Earnings Estimates for BCAX | 11/14/2025 |
4 | Disposition of 8000 shares by Cohlhepp Ryan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 11/21/2025 |
5 | Disposition of 906 shares by Raben David of Bicara Therapeutics at 18.8424 subject to Rule 16b-3 | 11/25/2025 |
6 | Why Bicara Therapeutics Is Up 18.6 percent After FDA Breakthrough Therapy Designation for Cancer Drug | 11/26/2025 |
7 | Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. BCAX | 12/03/2025 |
8 | Disposition of 9200 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 12/22/2025 |
9 | Disposition of 9744 shares by Meisner Lara of Bicara Therapeutics at 5.45 subject to Rule 16b-3 | 12/26/2025 |
| Begin Period Cash Flow | 230.4 M | |
| Total Cashflows From Investing Activities | -9000.00 |
Bicara Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,826 in Bicara Therapeutics Common on October 9, 2025 and sell it today you would lose (207.00) from holding Bicara Therapeutics Common or give up 11.34% of portfolio value over 90 days. Bicara Therapeutics Common is currently does not generate positive expected returns and assumes 4.0988% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Bicara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bicara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bicara Therapeutics Common, and traders can use it to determine the average amount a Bicara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0279
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCAX |
Based on monthly moving average Bicara Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bicara Therapeutics by adding Bicara Therapeutics to a well-diversified portfolio.
Bicara Therapeutics Fundamentals Growth
Bicara Stock prices reflect investors' perceptions of the future prospects and financial health of Bicara Therapeutics, and Bicara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bicara Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 609.14 M | ||||
| Shares Outstanding | 54.78 M | ||||
| Price To Book | 2.23 X | ||||
| EBITDA | (82.33 M) | ||||
| Net Income | (68 M) | ||||
| Total Debt | 738 K | ||||
| Book Value Per Share | 7.38 X | ||||
| Cash Flow From Operations | (74.75 M) | ||||
| Earnings Per Share | 5.38 X | ||||
| Market Capitalization | 882.54 M | ||||
| Total Asset | 569.2 M | ||||
| Retained Earnings | (221.02 M) | ||||
| Working Capital | 484.54 M | ||||
About Bicara Therapeutics Performance
Evaluating Bicara Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Bicara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bicara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.19) | (0.18) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.16) | (0.15) |
Things to note about Bicara Therapeutics performance evaluation
Checking the ongoing alerts about Bicara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bicara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bicara Therapeutics generated a negative expected return over the last 90 days | |
| Bicara Therapeutics has high historical volatility and very poor performance | |
| Bicara Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bicara Therapeutics generates negative cash flow from operations | |
| Bicara Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 9200 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 |
- Analyzing Bicara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bicara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bicara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bicara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bicara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bicara Therapeutics' stock. These opinions can provide insight into Bicara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.